Is Adagene Inc. (ADAG) a Buy, Sell, or Hold?
Adagene Inc.
NASDAQ:ADAG
$3.635 USD
$0.03 (0.69%)
- Volume
- 693.25
- Average Volume
- 235.68K
- Market Capitalization
- $136.85M
- P/E Ratio
- -7.70
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $4.85
- Year Low
- $1.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.07
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Peter Luo |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ADAG |
| CUSIP | 005329107 |
| CIK | 0001818838 |
| Web | https://www.adagene.com |
| Phone | 86 512 8777 3632 |
| Currency | USD |
| Employees | 128 |
| Country | CN |
Liquidity
| Debt-to-Equity Ratio | 0.18 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.07 |
| Quick Ratio | 3.07 |
| Cash Ratio | 2.96 |
Sales & Book Value
| Annual Sales | $7.67M |
| Price / Sales | 17.79 |
| Cash Flow | -0.41 |
| Price / Cash Flow | -8.71 |
| Price / Book | 3.90 |
Price Target and Rating
| Average Stock Price Forecast | $10.00 |
| High Stock Price Forecast | $10.00 |
| Low Stock Price Forecast | $10.00 |
| Forecast Upside/Downside | -63.65% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 5 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.46 |
| Trailing P/E Ratio | -7.70 |
| PEG Ratio | -0.08 |
| P/E Growth | -0.08 |
| Net Income | $-17.61M |
| Net Margin | -229.49% |
| Pretax Margin | -233.37% |
| Return on Equity | -48.20% |
| Return on Assets | -22.56% |
Financials Score
| AltmanZ Score | -5.19 |
| Piotroski Score | 5.00 |
| Working Capital | 52.2M |
| Total Assets | 78.26M |
| Ebit | -54.08M |
| Market Cap | 148.34M |
| Total Liabilities | 42.91M |
Poll Results
About Adagene Inc. (NASDAQ:ADAG) Stock
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid ... tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Adagene (ADAG) Upgraded to Buy: Here's What You Should Know
2026-06-05 13:00:30
Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Adagene (ADAG) This Year?
2026-06-02 10:41:10
Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer
2026-05-19 17:08:02
Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst Stephen Willey, emphasizing the company's focus on improving the therapeutic index of CTLA-4 inhibition through its proprietary masking technology.
Adagene to Participate in Two Upcoming Investor Conferences
2026-05-12 08:30:00
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in one-on-one investor meetings and a fireside chat at the Stifel Annual Virtual Oncology Event on May 19-20, 2026 and one-on-one investor meetings at the Jefferies LLC Global Healthcare Conference being held June 2-4, 2026 in New York, NY.
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Significant Growth in Short Interest
2026-04-26 03:13:08
Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 411,325 shares, a growth of 477.3% from the March 31st total of 71,244 shares. Approximately 1.1% of the shares of the stock
2026-04-17 16:01:00
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per HCC-specific Modified RECIST v1.1) as 1L therapy in a Phase 1b/2 trial in locally advanced or metastatic and/or unresectable hepatocellular carcinoma (HCC) patients
Adagene Looks Attractive With ADG126 And Validating Partnerships
2026-04-16 14:08:28
Adagene is essentially a single-asset bet on ADG126, which is a masked anti-CTLA-4 antibody designed to improve tolerability in immuno-oncology. ADG126's upcoming AACR 2026 updates are likely the biggest near-term catalysts to look forward to this year. ADAG also has partnerships with Sanofi and Incyte that validate its pipeline to some extent. These also open the door to potential milestone and royalty payments.
Frequently Asked Questions
-
What is the current Adagene Inc. (ADAG) stock price?
-
Adagene Inc.(NASDAQ:ADAG) stock price is $3.635 in the last trading session. During the trading session, ADAG stock reached the peak price of $4.85 while $1.3 was the lowest point it dropped to. The percentage change in ADAG stock occurred in the recent session was 0.69% while the dollar amount for the price change in ADAG stock was $0.03.
-
ADAG's industry and sector of operation?
-
The NASDAQ listed ADAG is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ADAG?
-
Yan Li | Senior Vice President of Bioinformatics & Information Technology
Alexander Goergen | Vice President & Head of Business Development
Guizhong Liu | Senior Vice President of Early Drug Discovery
Mickael Chane-Du | Chief Strategy Officer
Qinghai Zhao | Chief Manufacturing Officer -
How many employees does ADAG have?
-
Number of ADAG employees currently stands at 128. ADAG operates from Building C14, Suzhou, JS 215123, CN.
-
Link for ADAG official website?
-
Official Website of ADAG is: https://www.adagene.com
-
How do I contact ADAG?
-
ADAG could be contacted at phone #86 512 8777 3632 and can also be accessed through its website. ADAG operates from Building C14, Suzhou, JS 215123, CN.
-
How many shares of ADAG are traded daily?
-
The average number of ADAG shares traded daily for last 3 months was 235.68K.
-
What is the market cap of ADAG currently?
-
The market value of ADAG currently stands at $136.85M with its latest stock price at $3.635